1. Home
  2. MTEX vs PHGE Comparison

MTEX vs PHGE Comparison

Compare MTEX & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MTEX
  • PHGE
  • Stock Information
  • Founded
  • MTEX 1993
  • PHGE 2015
  • Country
  • MTEX United States
  • PHGE Israel
  • Employees
  • MTEX N/A
  • PHGE N/A
  • Industry
  • MTEX Medicinal Chemicals and Botanical Products
  • PHGE Biotechnology: Pharmaceutical Preparations
  • Sector
  • MTEX Health Care
  • PHGE Health Care
  • Exchange
  • MTEX Nasdaq
  • PHGE Nasdaq
  • Market Cap
  • MTEX 15.8M
  • PHGE 15.5M
  • IPO Year
  • MTEX 1999
  • PHGE N/A
  • Fundamental
  • Price
  • MTEX $8.89
  • PHGE $0.58
  • Analyst Decision
  • MTEX
  • PHGE Strong Buy
  • Analyst Count
  • MTEX 0
  • PHGE 1
  • Target Price
  • MTEX N/A
  • PHGE $15.00
  • AVG Volume (30 Days)
  • MTEX 48.5K
  • PHGE 431.9K
  • Earning Date
  • MTEX 11-07-2025
  • PHGE 11-13-2025
  • Dividend Yield
  • MTEX N/A
  • PHGE N/A
  • EPS Growth
  • MTEX N/A
  • PHGE N/A
  • EPS
  • MTEX N/A
  • PHGE N/A
  • Revenue
  • MTEX $112,975,000.00
  • PHGE N/A
  • Revenue This Year
  • MTEX N/A
  • PHGE N/A
  • Revenue Next Year
  • MTEX N/A
  • PHGE N/A
  • P/E Ratio
  • MTEX N/A
  • PHGE N/A
  • Revenue Growth
  • MTEX N/A
  • PHGE N/A
  • 52 Week Low
  • MTEX $7.22
  • PHGE $0.34
  • 52 Week High
  • MTEX $16.49
  • PHGE $1.16
  • Technical
  • Relative Strength Index (RSI)
  • MTEX 49.08
  • PHGE 53.20
  • Support Level
  • MTEX $8.76
  • PHGE $0.55
  • Resistance Level
  • MTEX $9.78
  • PHGE $0.63
  • Average True Range (ATR)
  • MTEX 0.63
  • PHGE 0.05
  • MACD
  • MTEX -0.03
  • PHGE -0.00
  • Stochastic Oscillator
  • MTEX 12.15
  • PHGE 34.53

About MTEX Mannatech Incorporated

Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Share on Social Networks: